AgomAb Therapeutics NV's IPO
Listed Feb 6, 2026 at $16 on Nasdaq as AGMB.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does AgomAb Therapeutics NV do?
“We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.”
| Fact | AgomAb Therapeutics NV |
|---|---|
| Employees | 62, as of December 31, 2025 |
| Website | agomab.com |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | AgomAb Therapeutics NV |
|---|---|
| Shares offered | 12,500,000 ADSs |
| Offer price | $16 per ADS |
| Raised at that price | $200 million |
| Underwriters' discount | $14 million |
| Net proceeds the company expects | About $181 million |
| Underwriters' option | 1,875,000 more ADSs |
| Underwriters | J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen |
| Exchange | Nasdaq Global Select Market, as AGMB |
| Shares outstanding after | 48,736,779 |
| Market cap at the offer price | $780 million |
What the filing says about its money
| Fact | AgomAb Therapeutics NV |
|---|---|
| Revenue | None from product sales yet |
| Last preferred stock | Series D preferred |
What risks does AgomAb Therapeutics NV name first?
- “We are a clinical-stage biopharmaceutical company and have incurred significant losses every year since our inception.”
- “Even if this offering is successful, we will need to raise additional funding, which may not be available on acceptable terms, or at all.”
- “The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.”
Every date of AgomAb Therapeutics NV's IPO
| What | Day |
|---|---|
| Registration filed | Jan 16, 2026 |
| Declared effective by the SEC | Jan 30, 2026 |
| Exchange registration filed | Feb 3, 2026 |
| Priced | Feb 5, 2026 |
| First trade | Feb 6, 2026 |
| Lock-up ends | Aug 4, 2026 |
How did its first days trade?
From its daily bars, each close against its $16 offer price.
| Day | Open | Close | From the offer |
|---|---|---|---|
| Feb 6 | $14.70 | $14.65 | -8.4% |
| Feb 9 | $14.55 | $15.61 | -2.4% |
| Feb 10 | $15 | $15.55 | -2.8% |
| Feb 11 | $14.53 | $16 | 0.0% |
| Feb 12 | $15.98 | $15.66 | -2.1% |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
AgomAb Therapeutics NV IPO questions
When is AgomAb Therapeutics NV's IPO?
Listed Feb 6, 2026 at $16 on Nasdaq as AGMB.
What is AgomAb Therapeutics NV's IPO price?
AgomAb Therapeutics NV's IPO priced at $16 a share, per its final prospectus of Feb 6, 2026.
How many shares is AgomAb Therapeutics NV selling?
12,500,000 ADSs, and the underwriters may buy 1,875,000 more, per its final prospectus (424B4).
Who are the underwriters?
J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, as the prospectus's cover names them.
When does the lock-up end?
AgomAb Therapeutics NV's IPO lock-up ends Aug 4, 2026. Its final prospectus says: “.”
Does Breakaway rate AgomAb Therapeutics NV?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where AgomAb Therapeutics NV's price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every new listing, ranked live, free. No account.
See all 16 new listings rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
Every IPO expected and listed, and February 2026's listings.